A Novel Serum Metabolomics-Based Diagnostic Approach to Pancreatic Cancer

Abstract

Background: To improve the prognosis of patients with pancreatic cancer, more accurate serum diagnostic methods are required. We used serum metabolomics as a diagnostic method for pancreatic cancer.Methods: Sera from patients with pancreatic cancer, healthy volunteers, and chronic pancreatitis were collected at multiple institutions. The pancreatic cancer and healthy volunteers were randomly allocated to the training or the validation set. All of the chronic pancreatitis cases were included in the validation set. In each study, the subjects' serum metabolites were analyzed by gas chromatography mass spectrometry (GC/MS) and a data processing system using an in-house library. The diagnostic model constructed via multiple logistic regression analysis in the training set study was evaluated on the basis of its sensitivity and specificity, and the results were confirmed by the validation set study.Results: In the training set study, which included 43 patients with pancreatic cancer and 42 healthy volunteers, the model possessed high sensitivity (86.0%) and specificity (88.1%) for pancreatic cancer. The use of the model was confirmed in the validation set study, which included 42 pancreatic cancer, 41 healthy volunteers, and 23 chronic pancreatitis; that is, it displayed high sensitivity (71.4%) and specificity (78.1%); and furthermore, it displayed higher sensitivity (77.8%) in resectable pancreatic cancer and lower false-positive rate (17.4%) in chronic pancreatitis than conventional markers.Conclusions: Our model possessed higher accuracy than conventional tumor markers at detecting the resectable patients with pancreatic cancer in cohort including patients with chronic pancreatitis.Impact: It is a promising method for improving the prognosis of pancreatic cancer via its early detection and accurate discrimination from chronic pancreatitis. Cancer Epidemiol Biomarkers Prev; 22(4); 571-9. Ó2013 AACR.

Early diagnosis of pancreatic cancer: Current trends and concerns

“…Recently, some panels of new potential biomarkers based on biological, immunological, and genetic changes of PC using blood samples or body fluids, such as urine and saliva, have been reported. A serum metabolomics‐based diagnostic model and salivary transcriptomic biomarkers for diagnosis of resectable PC are reported to possess higher accuracy than conventional markers 45, 46. Fukutake et al .…”

Pancreatic Cancer Screening: Attempts and Possibilities

“…A feasibility study attempting to identify pancreatic cancer using an elevated CA19-9 and the referral for EUS showed that in 546 patients with a single first degree relative with pancreatic cancer, only 1 pancreatic adenocarcinoma was found at a cost of more than $40,000 [10]. CA 19-9 in combination with newer screening modalities such as microRNA biomarkers in whole blood and serum metabolism profiling has shown improved sensitivity however their role in clinical practice has not yet been clarified [28,29].…”

A Narrative Review on the Current Application Biomarkers in the Management of Colorectal Cancer

“…The concept of altered cancer metabolism, described as the Warburg effect, where cancer cells preferentially convert glucose into lactate even in the presence of abundant oxygen, has been validated in a variety of cancer subtypes [55][56][57][58]. This serves as the support for using [18F]-fluorodeoxyglucose (FDG) enhanced positron emission tomography (FDG-PET) imaging of solid tumours, which shows glycolytic flux [54,59].…”